|   LifeSciVC

2018’s Biotech IPO Bonanza: View From the After Market

By Bruce Booth, DPhil, Partner


2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years.

Read more.